Angtai Microfine

Angtai Microfine Medical Technology (Shanghai) Co., Ltd. develops ultra-precision surgical robot platforms designed for microsurgical and ophthalmic applications. Founded in 2022, the company builds on over a decade of collaboration with medical device manufacturers in Japan and the United States, bringing Japanese precision manufacturing expertise to China’s surgical robotics sector.

Company Overview

Angtai Microfine emerged as a spinoff from technology developed through partnerships with international medical device companies dating back to 2011. The company positions itself as the first globally to focus exclusively on small-scale, precision surgical robot platforms capable of tremor-free operation throughout entire procedures.

The founding team, led by Mr. Watanabe, brings deep expertise in precision medical device manufacturing. The company operates research and development centers in the United States and Japan in addition to its Shanghai headquarters, supporting both domestic regulatory approval and international market expansion.

Angtai Microfine has established clinical collaborations with leading Chinese medical institutions including Shanghai Ninth People’s Hospital, Ningbo No.6 People’s Hospital, and Peking University School of Stomatology. The company has also formed a strategic partnership with Takeda Pharmaceutical.

Core Products

Kai General-Purpose Microsurgical Robot

The Kai system represents a platform-type microsurgical robot designed to assist procedures requiring precision beyond human hand capabilities. The system covers multiple specialties including reconstructive surgery, maxillofacial surgery, hand surgery, and microsurgical reconstruction.

Key specifications include:

• Sub-micrometer single-step motion accuracy
• Tremor-free operation throughout procedures
• 7 degrees of freedom wrist-type joint design
• Instrument tip diameter under 3mm (smallest globally)
• Capability to anastomose vessels as small as 0.3mm diameter

Ophthalmic Surgical Robot

Developed specifically for retinal and vitreoretinal surgery, this system addresses the precision demands of ophthalmic procedures where ideal instrument accuracy is 10 micrometers—far exceeding the approximately 100 micrometers of inherent human hand tremor.

The ophthalmic robot completed product type testing in 2024 and entered clinical trials, with registration approval targeted for 2025.

Gastrointestinal Endoscopy Robot

Under development for transendoscopic procedures, this system extends the company’s precision platform technology to gastrointestinal applications.

Otology Surgical Robot

Also in development, this system applies the company’s microsurgical technology to ear surgery applications.

Technology & Innovation

Angtai Microfine is a Shanghai-based microsurgery robotics firm built on Japanese precision manufacturing expertise, featuring sub-micrometer accuracy and the world’s smallest wrist-type forceps at 2mm diameter.

Angtai Microfine’s core technological achievement lies in becoming the first company globally to achieve completely tremor-free surgical robot operation. The proprietary drive system eliminates vibration throughout procedures, while the company’s precision instruments represent the world’s smallest wrist-type forceps at 2mm diameter.

The technology platform enables:

• Anastomosis of 0.3mm diameter capillaries and lymphatic vessels
• Needle gauge breakthrough to sub-48G outer diameter (approaching world’s smallest)
• Compact system footprint—7 times smaller than da Vinci systems
• Rapid deployment across different operating room configurations

All core components including servo systems and transmission mechanisms are developed in-house, providing full intellectual property ownership and manufacturing control.

Market Presence

The company targets the emerging microsurgical robot market, where only two systems have achieved CE certification globally: the Symani system from Medical Microinstruments (Italy) and the MUSA system from Microsure (Netherlands). In China, the microsurgical and ophthalmic robot segments remain largely unaddressed by domestic manufacturers.

Angtai Microfine plans to establish a U.S. subsidiary to pursue FDA registration in parallel with NMPA approval in China, supported by investment from Temasek and other international investors.

Key Milestones

• 2011: Began technology development collaboration with Japanese and American medical device companies
• 2022: Founded Angtai Microfine Medical Technology (Shanghai) Co., Ltd.
• 2022 (September): Completed Series A financing led by Qiming Venture Partners
• 2022 (December): Completed Series A+ financing from Temasek
• 2024: Kai microsurgical robot entered animal testing phase
• 2024: Ophthalmic robot completed type testing and entered clinical trials
• 2025 (September): Completed Series B financing

Frequently Asked Questions

What makes Angtai Microfine’s technology unique?

Angtai Microfine claims to be the first company globally to achieve completely tremor-free surgical robot operation. The system’s sub-micrometer precision and 2mm diameter wrist-type instruments enable procedures on vessels as small as 0.3mm—beyond the capabilities of human hands with their inherent 100-micrometer physiological tremor.

What surgical specialties does Angtai Microfine serve?

The company’s platform covers microsurgery (reconstructive, maxillofacial, hand surgery), ophthalmology (retinal surgery), gastroenterology (endoscopic procedures), and otology (ear surgery). The general-purpose Kai system can also complement other surgical robots like orthopedic or laparoscopic systems for high-precision portions of procedures.

Is Angtai Microfine publicly traded?

No, Angtai Microfine remains a private company. As of September 2025, the company has completed Series B financing with backing from investors including Qiming Venture Partners, Temasek, and other institutional investors.